Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
Roche implements risk mitigation plan in taspoglutide Phase III programme

Roche implements risk mitigation plan in taspoglutide Phase III programme

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Health Canada approves Victoza for treatment of adults with type 2 diabetes

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Biotech reports record financial results for 2010 first quarter

Biotech reports record financial results for 2010 first quarter

Patients switching to Victoza experience further reductions in A1c and weight loss

Patients switching to Victoza experience further reductions in A1c and weight loss

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

NDA for BYDUREON: FDA issues complete response letter

NDA for BYDUREON: FDA issues complete response letter

FDA sets new PDUFA action date for exenatide once weekly NDA

FDA sets new PDUFA action date for exenatide once weekly NDA

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Positive results from study comparing exenatide once weekly to BYETTA

Positive results from study comparing exenatide once weekly to BYETTA

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

Roche announces results of phase III taspoglutide study in diabetes patients

Roche announces results of phase III taspoglutide study in diabetes patients

US Patent & Trademark Office allows patent application for NOD technology

US Patent & Trademark Office allows patent application for NOD technology

Shanghai Biolaxy receives IND approval for insulin formulation to treat diabetes

Shanghai Biolaxy receives IND approval for insulin formulation to treat diabetes

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA updates Byetta prescribing information following reports of kidney problems

FDA updates Byetta prescribing information following reports of kidney problems